This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Reasons to Retain Bio-Rad (BIO) Stock in Your Portfolio Now
by Zacks Equity Research
Bio-Rad's (BIO) robust digital PCR business and Clinical Diagnostics segments raise optimism. However, macro issues raise concerns.
Globus Medical's (GMED) Lateral Interbody Portfolio Gets New Launch
by Zacks Equity Research
Globus Medical's (GMED) lateral interbody portfolio gets its first commercial product launch with ADIRA XLIF Plate System.
IQVIA (IQV) Up 3.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
IQVIA (IQV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Reasons to Retain Thermo Fisher (TMO) in Your Portfolio Now
by Zacks Equity Research
Strategic alliances and impressive product launches bode well for Thermo Fisher (TMO).
Omnicell (OMCL) Introduces Central Med Automation Service
by Zacks Equity Research
Omnicell (OMCL) has come up with a subscription-based solution named Central Med Automation Service. The solution is expected to improve inventory visibility, scalability and patient safety.
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.
Alcon (ALC) Q2 Earnings Meet Estimates, Revenues Increase Y/Y
by Zacks Equity Research
Alcon (ALC) delivers impressive growth in Implantables and Contact Lenses in the second quarter of 2024.
Medtronic (MDT) Q1 Earnings Beat, Fiscal 2025 View Narrowed
by Zacks Equity Research
Medtronic (MDT) reports broad-based growth across all major segments, with strong gains in Cardiac Rhythm & Heart Failure, Structural Heart & Aortic, Cranial & Spinal Technologies and Diabetes businesses.
NeuroPace (NPCE) Q2 Earnings Beat, '24 Sales View Up
by Zacks Equity Research
NeuroPace's (NPCE) top and bottom lines outpace estimates in the second quarter.
Paragon 28 (FNA) Expands SMART 28 Ecosystem With New Launches
by Zacks Equity Research
Paragon 28 (FNA) strengthens its position in the foot and ankle device market with the launch of the SMART28 Case Management Portal and the SMART Bun-Yo-Matic device.
Compelling Reasons to Hold Molina Healthcare (MOH) Stock Now
by Zacks Equity Research
Molina Healthcare (MOH) remains well-poised for growth, attributable to membership growth in Medicaid and Medicare businesses. Buyouts and an adequate cash balance remain other benefits.
Reasons to Add Intuitive Surgical (ISRG) to Your Portfolio Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to raise optimism among investors owing to its strength in robotics.
Haemonetics (HAE) Set to Launch VASCADE MVP XL in US
by Zacks Equity Research
Haemonetics (HAE) expands its VASCADE portfolio with the full market release of the VASCADE MVP XL vascular closure device in the U.S. market.
Accuray's (ARAY) Radixact for Cancer Treatment Debuts in US
by Zacks Equity Research
Accuray's (ARAY) Radixact System with VitalHold technology is set to enhance precision and comfort in radiation therapy.
Is Intuitive Surgical (ISRG) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Intuitive Surgical (ISRG) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Stereotaxis (STXS) Achieves CE Mark in Europe for GenesisX
by Zacks Equity Research
Stereotaxis (STXS) gets a CE mark in Europe for its GenesisX robotic system. Following this, the company also submits a 501(k) application for FDA clearance.
Inflation Cools in July: 4 Sector ETFs & Stocks to Thrive
by Sanghamitra Saha
The annual inflation rate in the United States slowed for a fourth successive month in July 2024.
Labcorp (LH) Gains From New Collaborations Amid FX Issues
by Zacks Equity Research
Labcorp's (LH) Biopharma Laboratory Services business is benefiting from collaborations with leading pharmaceutical and biotechnology companies.
Accelerate Diagnostics (AXDX) Completes WAVE Pre-Clinical Trial
by Zacks Equity Research
Accelerate Diagnostics (AXDX) is confident about WAVE product design and the system's capabilities after the successful completion of the pre-clinical trial.
Here is What to Know Beyond Why Intuitive Surgical, Inc. (ISRG) is a Trending Stock
by Zacks Equity Research
Zacks.com users have recently been watching Intuitive Surgical (ISRG) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Neuronetics (STIM) Inks a New Merger Agreement With Greenbrook
by Zacks Equity Research
Neuronetics (STIM) signs a merger agreement with Greenbrook to acquire all its outstanding shares. The transaction is expected to be closed during the fourth quarter of 2024.
Can Intuitive Surgical (ISRG) Run Higher on Rising Earnings Estimates?
by Zacks Equity Research
Intuitive Surgical (ISRG) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Quest Diagnostics (DGX) Gains From Innovation, Customer Wins
by Zacks Equity Research
A key driver in Brain Health growth is Quest Diagnostics' (DGX) Alzheimer's disease portfolio, featuring the AD-Detect blood testing services and the CSF Tests for diagnosing and monitoring.
Neuronetics (STIM) Q2 Loss Wider Than Expected, Revenues Fall Y/Y
by Zacks Equity Research
Neuronetics' (STIM) second-quarter 2024 top-line results reflect lower revenues from NeuroStar Advanced Therapy System and Treatment sessions.
Here's How Much a $1000 Investment in Intuitive Surgical, Inc. Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.